MorphoSys AG ADR
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $7.88
- Today's High:
- $8.1
- Open Price:
- $7.9
- 52W Low:
- $3.17
- 52W High:
- $8.67
- Prev. Close:
- $7.97
- Volume:
- 69989
Company Statistics
- Market Cap.:
- $1.03 billion
- Book Value:
- 0.2318
- Revenue TTM:
- $292.84 million
- Operating Margin TTM:
- -71.51%
- Gross Profit TTM:
- $229.65 million
- Profit Margin:
- 30.11%
- Return on Assets TTM:
- -5.63%
- Return on Equity TTM:
- 41.89%
Company Profile
MorphoSys AG ADR had its IPO on 1999-03-09 under the ticker symbol MOR.
The company operates in the Healthcare sector and Biotechnology industry. MorphoSys AG ADR has a staff strength of 544 employees.
Stock update
Shares of MorphoSys AG ADR opened at $7.9 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $7.88 - $8.1, and closed at $8.08.
This is a +1.38% increase from the previous day's closing price.
A total volume of 69,989 shares were traded at the close of the day’s session.
In the last one week, shares of MorphoSys AG ADR have increased by +8.89%.
MorphoSys AG ADR's Key Ratios
MorphoSys AG ADR has a market cap of $1.03 billion, indicating a price to book ratio of 5.409 and a price to sales ratio of 2.1842.
In the last 12-months MorphoSys AG ADR’s revenue was $292.84 million with a gross profit of $229.65 million and an EBITDA of $-202313200. The EBITDA ratio measures MorphoSys AG ADR's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, MorphoSys AG ADR’s operating margin was -71.51% while its return on assets stood at -5.63% with a return of equity of 41.89%.
In Q2, MorphoSys AG ADR’s quarterly earnings growth was a positive 0% while revenue growth was a negative 10.6%.
MorphoSys AG ADR’s PE and PEG Ratio
- Forward PE
- 322.5806
- Trailing PE
- 10.9118
- PEG
Its diluted EPS in the last 12-months stands at $0.68 per share while it has a forward price to earnings multiple of 322.5806 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into MorphoSys AG ADR’s profitability.
MorphoSys AG ADR stock is trading at a EV to sales ratio of 0.6201 and a EV to EBITDA ratio of -0.3027. Its price to sales ratio in the trailing 12-months stood at 2.1842.
MorphoSys AG ADR stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $2.14 billion
- Total Liabilities
- $241.70 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $102097
- Dividend Payout Ratio
- 0%
MorphoSys AG ADR ended 2024 with $2.14 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $2.14 billion while shareholder equity stood at $31.67 million.
MorphoSys AG ADR ended 2024 with $0 in deferred long-term liabilities, $241.70 million in other current liabilities, 34231943.00 in common stock, $-941806215.00 in retained earnings and $349.71 million in goodwill. Its cash balance stood at $184.33 million and cash and short-term investments were $671.77 million. The company’s total short-term debt was $5,177,468 while long-term debt stood at $239.52 million.
MorphoSys AG ADR’s total current assets stands at $862.87 million while long-term investments were $4.07 million and short-term investments were $487.44 million. Its net receivables were $86.18 million compared to accounts payable of $119.82 million and inventory worth $71.73 million.
In 2024, MorphoSys AG ADR's operating cash flow was $0 while its capital expenditure stood at $102097.
Comparatively, MorphoSys AG ADR paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $8.08
- 52-Week High
- $8.67
- 52-Week Low
- $3.17
- Analyst Target Price
- $9.69
MorphoSys AG ADR stock is currently trading at $8.08 per share. It touched a 52-week high of $8.67 and a 52-week low of $8.67. Analysts tracking the stock have a 12-month average target price of $9.69.
Its 50-day moving average was $7.75 and 200-day moving average was $5.69 The short ratio stood at 0.53 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 989.7% are held by institutions.
Frequently Asked Questions About MorphoSys AG ADR
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule to treat myelofibrosis; Felzartamab, an antibody directed against CD38 for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule to promote anti-tumor activity by inhibiting EZH2 and EZH1. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer’s diseases; and Otilimab, an antibody for rheumatoid arthritis. The company has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.